EVAX Evaxion Biotech A/S ADRs
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$1.24 +0.08 (6.90%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Denmark
Country of incorporation:
IPO date: 02/04/2021
Outstanding shares: 23,833,694
Average volume: 73,446
Market cap: $27,647,085
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%